{"id":147701,"date":"2025-04-23T16:08:46","date_gmt":"2025-04-23T10:38:46","guid":{"rendered":"https:\/\/tradebrains.in\/features\/?p=147701"},"modified":"2025-04-23T16:08:50","modified_gmt":"2025-04-23T10:38:50","slug":"pharma-stock-jumps-5-after-receiving-usfda-approval-to-manufacture-cancer-treating-drug","status":"publish","type":"post","link":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-5-after-receiving-usfda-approval-to-manufacture-cancer-treating-drug\/","title":{"rendered":"Pharma stock jumps 5% after receiving USFDA approval to manufacture cancer-treating drug"},"content":{"rendered":"<div class=\"trade-content_2\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-2938536914\"><p><a href=\"https:\/\/tradebrains.in\/get\/telegram\/\"><img decoding=\"async\" class=\"alignnone wp-image-101992\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2023\/01\/telegram-channel-300x119.png\" alt=\"\" width=\"148\" height=\"59\" \/><\/a> <a href=\"https:\/\/news.google.com\/publications\/CAAqBwgKMN3Epgswxc--Aw?hl=en-IN&amp;gl=IN&amp;ceid=IN%3Aen\"><img decoding=\"async\" class=\"alignnone wp-image-123430\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png\" alt=\"follow-on-google-news\" width=\"222\" height=\"61\" srcset=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-300x82.png 300w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news-150x41.png 150w, https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/follow-on-google-news.png 468w\" sizes=\"(max-width: 222px) 100vw, 222px\" \/><\/a><\/p>\n<\/div><p>The shares of the Mid-Cap company specializing in the development, manufacturing, and commercialization of generic pharmaceuticals, active pharmaceutical ingredients (APIs), and branded specialty pharmaceuticals globally, jumped upto 5 percent following the USFDA approval to manufacture and market Dasatinib Tablets.<\/p><div class=\"trade-content_7\" style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"trade-1378853194\"><!-- Composite Start --> \r\n <div id=\"M923760ScriptRootC1549812\"> \r\n <\/div> \r\n <script src=\"https:\/\/jsc.mgid.com\/t\/r\/tradebrains.in.1549812.js\" async> \r\n <\/script> \r\n <!-- Composite End --><\/div><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Price action<\/strong><\/h2><p>With a market capitalization of Rs. 72,295.28 crores on Wednesday, the shares of <strong><a href=\"https:\/\/portal.tradebrains.in\/stocks\/AUROPHARMA\" target=\"_blank\" rel=\"noreferrer noopener\">Aurobindo Pharma Limited<\/a> <\/strong>jumped upto 4.8 percent, making a high of Rs. 1246.00 per share compared to its previous closing price of Rs. 1188.10\u00a0 per share.<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>What Happened<\/strong><\/h2><p>Aurobindo Pharma Limited has announced that its wholly owned subsidiary, Eugia Pharma Specialities Limited, has received final approval from the USFDA to manufacture and market Dasatinib Tablets in various strengths (20 mg to 140 mg). These tablets are the generic equivalent of Sprycel by Bristol-Myers Squibb and are used to treat certain types of leukemia (Cancer).&nbsp;<\/p><p>This approval marks an important milestone for Eugia, adding to its strong portfolio of oncology products. The product is expected to launch in Q1FY26 and has an estimated market size of $1.8 billion (as of February 2025).<\/p><div class=\"trade-content_5\" id=\"trade-217548681\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_2_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"7925020301\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Management Guidance&nbsp;<\/strong><\/h2><p>According to the company\u2019s recent conference call update, they target EBITDA margins of 21 percent to 22 percent in the upcoming years.<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Capacity Expansion<\/strong><\/h2><p>According to the management, a CDMO capacity addition of 30 KL (kilolitres) is being undertaken in anticipation of future demand. The rationale is that when a facility is designed for four 15 KL bioreactor capacities, only two lines are built initially, while the remaining two are reserved for Phase 2 expansion.<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Revenue Mix&nbsp;<\/strong><\/h2><p>In Q3FY25, the revenue mix for the company was as follows: 68.4 percent came from Generic Orals, 17.6 percent from Specialty &amp; Injectables, 7.5 percent from Branded Oncology, and 6.5 percent from Over-the-Counter (OTC) products.<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>About the Company<\/strong><\/h2><p>Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients globally in over 150 countries.<\/p><h2 class=\"wp-block-heading has-medium-font-size\"><strong>Financials&nbsp;<\/strong><\/h2><p>The company&#8217;s revenue rose by 8.27 percent from Rs. 7,514.3 crore to Rs. 8,135.81 crore in Q3FY24-25. Meanwhile, the Net profit declined from Rs. 936.29 crore to Rs. 845.81 crore during the same period.<\/p><blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><strong>Written by Sridhar J&nbsp;<\/strong><\/p><\/blockquote><p class=\"has-medium-font-size\"><strong>Disclaimer<\/strong><\/p><div class=\"trade-content-10\" id=\"trade-235841266\"><script async src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-4023722985638610\"\r\n     crossorigin=\"anonymous\"><\/script>\r\n<!-- in_content_3_news -->\r\n<ins class=\"adsbygoogle\"\r\n     style=\"display:block\"\r\n     data-ad-client=\"ca-pub-4023722985638610\"\r\n     data-ad-slot=\"2969612066\"\r\n     data-ad-format=\"auto\"\r\n     data-full-width-responsive=\"true\"><\/ins>\r\n<script>\r\n     (adsbygoogle = window.adsbygoogle || []).push({});\r\n<\/script><\/div><div class=\"wp-block-image\"><figure class=\"aligncenter size-medium\"><img decoding=\"async\" width=\"300\" height=\"300\" src=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2022\/02\/warning-disclaimer-300x300.png\" alt=\"\" class=\"wp-image-26306\"\/><\/figure><\/div><p><strong>The views and investment tips expressed by investment experts\/broking houses\/rating agencies on <a href=\"http:\/\/tradebrains.in\/\">tradebrains.in<\/a> are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing<\/strong>.<\/p><div class=\"trade-after-content\" id=\"trade-286209728\"><div id=\"taboola-below-article-thumbnails\"><\/div>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({\r\n    mode: 'alternating-thumbnails-a',\r\n    container: 'taboola-below-article-thumbnails',\r\n    placement: 'Below Article Thumbnails',\r\n    target_type: 'mix'\r\n  });\r\n<\/script>\r\n<script type=\"text\/javascript\">\r\n  window._taboola = window._taboola || [];\r\n  _taboola.push({flush: true});\r\n<\/script><\/div>","protected":false},"excerpt":{"rendered":"<p>The shares of the Mid-Cap company specializing in the development, manufacturing, and commercialization of generic pharmaceuticals, active pharmaceutical ingredients (APIs), and branded specialty pharmaceuticals globally, jumped upto 5 percent following the USFDA approval to manufacture and market Dasatinib Tablets. Price action With a market capitalization of Rs. 72,295.28 crores on Wednesday, the shares of Aurobindo [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":125304,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[31,1789],"tags":[1734,12635,9217,25690,24885,9216,948,936,2597],"class_list":["post-147701","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-trending-news","tag-aurobindo-pharma","tag-aurobindo-pharma-cancer-drug","tag-aurobindo-pharma-latest-news","tag-aurobindo-pharma-limited","tag-aurobindo-pharma-news","tag-aurobindo-pharma-share-price","tag-stock-market","tag-stock-market-news","tag-stocks-to-watch"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.5 (Yoast SEO v25.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma stock jumps 5% after receiving USFDA approval to manufacture cancer-treating drug - Trade Brains Features<\/title>\n<meta name=\"description\" content=\"The shares of the Mid-Cap company specializing in the development, manufacturing, and commercialization of generic pharmaceuticals, active pharmaceutical ingredients (APIs), and branded specialty pharmaceuticals globally, jumped upto 5 percent following the USFDA approval to manufacture and market Dasatinib Tablets.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-5-after-receiving-usfda-approval-to-manufacture-cancer-treating-drug\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma stock jumps 5% after receiving USFDA approval to manufacture cancer-treating drug\" \/>\n<meta property=\"og:description\" content=\"The shares of the Mid-Cap company specializing in the development, manufacturing, and commercialization of generic pharmaceuticals, active pharmaceutical ingredients (APIs), and branded specialty pharmaceuticals globally, jumped upto 5 percent following the USFDA approval to manufacture and market Dasatinib Tablets.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-5-after-receiving-usfda-approval-to-manufacture-cancer-treating-drug\/\" \/>\n<meta property=\"og:site_name\" content=\"Trade Brains Features\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TradeBrainsOfficial\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-23T10:38:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-23T10:38:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/USFDA.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"854\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Trade Brains\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:site\" content=\"@TradeBrainsGrp\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Trade Brains\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-5-after-receiving-usfda-approval-to-manufacture-cancer-treating-drug\/\",\"url\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-5-after-receiving-usfda-approval-to-manufacture-cancer-treating-drug\/\",\"name\":\"Pharma stock jumps 5% after receiving USFDA approval to manufacture cancer-treating drug - Trade Brains Features\",\"isPartOf\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-5-after-receiving-usfda-approval-to-manufacture-cancer-treating-drug\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-5-after-receiving-usfda-approval-to-manufacture-cancer-treating-drug\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/USFDA.jpg\",\"datePublished\":\"2025-04-23T10:38:46+00:00\",\"dateModified\":\"2025-04-23T10:38:50+00:00\",\"author\":{\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\"},\"description\":\"The shares of the Mid-Cap company specializing in the development, manufacturing, and commercialization of generic pharmaceuticals, active pharmaceutical ingredients (APIs), and branded specialty pharmaceuticals globally, jumped upto 5 percent following the USFDA approval to manufacture and market Dasatinib Tablets.\",\"breadcrumb\":{\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-5-after-receiving-usfda-approval-to-manufacture-cancer-treating-drug\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-5-after-receiving-usfda-approval-to-manufacture-cancer-treating-drug\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-5-after-receiving-usfda-approval-to-manufacture-cancer-treating-drug\/#primaryimage\",\"url\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/USFDA.jpg\",\"contentUrl\":\"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/USFDA.jpg\",\"width\":1280,\"height\":854},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-5-after-receiving-usfda-approval-to-manufacture-cancer-treating-drug\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/tradebrains.in\/features\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharma stock jumps 5% after receiving USFDA approval to manufacture cancer-treating drug\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/tradebrains.in\/features\/#website\",\"url\":\"https:\/\/tradebrains.in\/features\/\",\"name\":\"Trade Brains\",\"description\":\"Stock Market NSE\/BSE Latest News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/tradebrains.in\/features\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666\",\"name\":\"Trade Brains\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g\",\"caption\":\"Trade Brains\"},\"sameAs\":[\"http:\/\/tradebrains.in\/\"],\"url\":\"https:\/\/tradebrains.in\/features\/author\/trade-brains\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma stock jumps 5% after receiving USFDA approval to manufacture cancer-treating drug - Trade Brains Features","description":"The shares of the Mid-Cap company specializing in the development, manufacturing, and commercialization of generic pharmaceuticals, active pharmaceutical ingredients (APIs), and branded specialty pharmaceuticals globally, jumped upto 5 percent following the USFDA approval to manufacture and market Dasatinib Tablets.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-5-after-receiving-usfda-approval-to-manufacture-cancer-treating-drug\/","og_locale":"en_US","og_type":"article","og_title":"Pharma stock jumps 5% after receiving USFDA approval to manufacture cancer-treating drug","og_description":"The shares of the Mid-Cap company specializing in the development, manufacturing, and commercialization of generic pharmaceuticals, active pharmaceutical ingredients (APIs), and branded specialty pharmaceuticals globally, jumped upto 5 percent following the USFDA approval to manufacture and market Dasatinib Tablets.","og_url":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-5-after-receiving-usfda-approval-to-manufacture-cancer-treating-drug\/","og_site_name":"Trade Brains Features","article_publisher":"https:\/\/www.facebook.com\/TradeBrainsOfficial\/","article_published_time":"2025-04-23T10:38:46+00:00","article_modified_time":"2025-04-23T10:38:50+00:00","og_image":[{"width":1280,"height":854,"url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/USFDA.jpg","type":"image\/jpeg"}],"author":"Trade Brains","twitter_card":"summary_large_image","twitter_creator":"@TradeBrainsGrp","twitter_site":"@TradeBrainsGrp","twitter_misc":{"Written by":"Trade Brains","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-5-after-receiving-usfda-approval-to-manufacture-cancer-treating-drug\/","url":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-5-after-receiving-usfda-approval-to-manufacture-cancer-treating-drug\/","name":"Pharma stock jumps 5% after receiving USFDA approval to manufacture cancer-treating drug - Trade Brains Features","isPartOf":{"@id":"https:\/\/tradebrains.in\/features\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-5-after-receiving-usfda-approval-to-manufacture-cancer-treating-drug\/#primaryimage"},"image":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-5-after-receiving-usfda-approval-to-manufacture-cancer-treating-drug\/#primaryimage"},"thumbnailUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/USFDA.jpg","datePublished":"2025-04-23T10:38:46+00:00","dateModified":"2025-04-23T10:38:50+00:00","author":{"@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666"},"description":"The shares of the Mid-Cap company specializing in the development, manufacturing, and commercialization of generic pharmaceuticals, active pharmaceutical ingredients (APIs), and branded specialty pharmaceuticals globally, jumped upto 5 percent following the USFDA approval to manufacture and market Dasatinib Tablets.","breadcrumb":{"@id":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-5-after-receiving-usfda-approval-to-manufacture-cancer-treating-drug\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tradebrains.in\/features\/pharma-stock-jumps-5-after-receiving-usfda-approval-to-manufacture-cancer-treating-drug\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-5-after-receiving-usfda-approval-to-manufacture-cancer-treating-drug\/#primaryimage","url":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/USFDA.jpg","contentUrl":"https:\/\/tradebrains.in\/features\/wp-content\/uploads\/2024\/05\/USFDA.jpg","width":1280,"height":854},{"@type":"BreadcrumbList","@id":"https:\/\/tradebrains.in\/features\/pharma-stock-jumps-5-after-receiving-usfda-approval-to-manufacture-cancer-treating-drug\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tradebrains.in\/features\/"},{"@type":"ListItem","position":2,"name":"Pharma stock jumps 5% after receiving USFDA approval to manufacture cancer-treating drug"}]},{"@type":"WebSite","@id":"https:\/\/tradebrains.in\/features\/#website","url":"https:\/\/tradebrains.in\/features\/","name":"Trade Brains","description":"Stock Market NSE\/BSE Latest News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tradebrains.in\/features\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/640937d840c7695c8f8995dd15ae0666","name":"Trade Brains","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tradebrains.in\/features\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bd7d6331c5ab74181158fb2f0f0d9eada16909507ed513a20867478cf3bbdd43?s=96&d=mm&r=g","caption":"Trade Brains"},"sameAs":["http:\/\/tradebrains.in\/"],"url":"https:\/\/tradebrains.in\/features\/author\/trade-brains\/"}]}},"_links":{"self":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/147701","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/comments?post=147701"}],"version-history":[{"count":1,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/147701\/revisions"}],"predecessor-version":[{"id":147702,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/posts\/147701\/revisions\/147702"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media\/125304"}],"wp:attachment":[{"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/media?parent=147701"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/categories?post=147701"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tradebrains.in\/features\/wp-json\/wp\/v2\/tags?post=147701"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}